These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 31411988)

  • 1. Loss of PTEN Expression Detected by Fluorescence Immunohistochemistry Predicts Lethal Prostate Cancer in Men Treated with Prostatectomy.
    Hamid AA; Gray KP; Huang Y; Bowden M; Pomerantz M; Loda M; Sweeney CJ
    Eur Urol Oncol; 2019 Sep; 2(5):475-482. PubMed ID: 31411988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparing Prognostic Utility of a Single-marker Immunohistochemistry Approach with Commercial Gene Expression Profiling Following Radical Prostatectomy.
    Leapman MS; Nguyen HG; Cowan JE; Xue L; Stohr B; Simko J; Cooperberg MR; Carroll PR
    Eur Urol; 2018 Nov; 74(5):668-675. PubMed ID: 30181067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer.
    Ahearn TU; Pettersson A; Ebot EM; Gerke T; Graff RE; Morais CL; Hicks JL; Wilson KM; Rider JR; Sesso HD; Fiorentino M; Flavin R; Finn S; Giovannucci EL; Loda M; Stampfer MJ; De Marzo AM; Mucci LA; Lotan TL
    J Natl Cancer Inst; 2016 Feb; 108(2):. PubMed ID: 26615022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined loss of TFF3 and PTEN is associated with lethal outcome and overall survival in men with prostate cancer.
    Abou-Ouf H; Ghosh S; Box A; Palanisamy N; Bismar TA
    J Cancer Res Clin Oncol; 2019 Jul; 145(7):1751-1759. PubMed ID: 31129769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of PTEN expression is associated with increased risk of recurrence after prostatectomy for clinically localized prostate cancer.
    Chaux A; Peskoe SB; Gonzalez-Roibon N; Schultz L; Albadine R; Hicks J; De Marzo AM; Platz EA; Netto GJ
    Mod Pathol; 2012 Nov; 25(11):1543-9. PubMed ID: 22684219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The 17-Gene Genomic Prostate Score Assay Predicts Outcome After Radical Prostatectomy Independent of PTEN Status.
    Magi-Galluzzi C; Isharwal S; Falzarano SM; Tsiatis A; Dee A; Maddala T; Knezevic D; Febbo PG; Lawrence J; Klein EA
    Urology; 2018 Nov; 121():132-138. PubMed ID: 30142405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PTEN Loss in Gleason Score 3 + 4 = 7 Prostate Biopsies is Associated with Nonorgan Confined Disease at Radical Prostatectomy.
    Guedes LB; Tosoian JJ; Hicks J; Ross AE; Lotan TL
    J Urol; 2017 Apr; 197(4):1054-1059. PubMed ID: 27693448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomy.
    Antonarakis ES; Keizman D; Zhang Z; Gurel B; Lotan TL; Hicks JL; Fedor HL; Carducci MA; De Marzo AM; Eisenberger MA
    Cancer; 2012 Dec; 118(24):6063-71. PubMed ID: 22674438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PTEN Loss but Not ERG Expression in Diagnostic Biopsies Is Associated with Increased Risk of Progression and Adverse Surgical Findings in Men with Prostate Cancer on Active Surveillance.
    Lokman U; Erickson AM; Vasarainen H; Rannikko AS; Mirtti T
    Eur Urol Focus; 2018 Dec; 4(6):867-873. PubMed ID: 28753869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The inflammation-related biomarker CXCR7 independently predicts patient outcome after radical prostatectomy.
    Bargão Santos P; Lobo J; Félix A; Silva F; Manso RT; Costa JO; Lourenço B; Sequeira JP; Jerónimo C; Patel HHR; Henrique R
    Urol Oncol; 2020 Oct; 38(10):794.e17-794.e27. PubMed ID: 32278731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multicenter study shows PTEN deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer.
    Troyer DA; Jamaspishvili T; Wei W; Feng Z; Good J; Hawley S; Fazli L; McKenney JK; Simko J; Hurtado-Coll A; Carroll PR; Gleave M; Lance R; Lin DW; Nelson PS; Thompson IM; True LD; Brooks JD; Squire JA
    Prostate; 2015 Aug; 75(11):1206-15. PubMed ID: 25939393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overexpression of the Long Non-coding RNA SChLAP1 Independently Predicts Lethal Prostate Cancer.
    Mehra R; Udager AM; Ahearn TU; Cao X; Feng FY; Loda M; Petimar JS; Kantoff P; Mucci LA; Chinnaiyan AM
    Eur Urol; 2016 Oct; 70(4):549-552. PubMed ID: 26724257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of ERG and Wild-Type PTEN Are Associated with Favorable Clinical Prognosis and Low Biochemical Recurrence in Prostate Cancer.
    Kim SH; Kim SH; Joung JY; Lee GK; Hong EK; Kang KM; Yu A; Nam BH; Chung J; Seo HK; Park WS; Lee KH
    PLoS One; 2015; 10(4):e0122498. PubMed ID: 25897494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer.
    Hamid AA; Gray KP; Shaw G; MacConaill LE; Evan C; Bernard B; Loda M; Corcoran NM; Van Allen EM; Choudhury AD; Sweeney CJ
    Eur Urol; 2019 Jul; 76(1):89-97. PubMed ID: 30553611
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Haney NM; Faisal FA; Lu J; Guedes LB; Reuter VE; Scher HI; Eastham JA; Marchionni L; Joshu C; Gopalan A; Lotan TL
    J Urol; 2020 Feb; 203(2):344-350. PubMed ID: 31502941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PTEN loss in biopsy tissue predicts poor clinical outcomes in prostate cancer.
    Mithal P; Allott E; Gerber L; Reid J; Welbourn W; Tikishvili E; Park J; Younus A; Sangale Z; Lanchbury JS; Stone S; Freedland SJ
    Int J Urol; 2014 Dec; 21(12):1209-14. PubMed ID: 25099119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of mTOR Pathway Markers and Clinical Outcomes in Patients with Intermediate-/High-risk Prostate Cancer: Long-Term Analysis.
    Barata PC; Magi-Galluzzi C; Gupta R; Dreicer R; Klein EA; Garcia JA
    Clin Genitourin Cancer; 2019 Oct; 17(5):366-372. PubMed ID: 31262501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Artificial Intelligence-Based PTEN Loss Assessment as an Early Predictor of Prostate Cancer Metastasis After Surgery: A Multicenter Retrospective Study.
    Patel P; Harmon S; Iseman R; Ludkowski O; Auman H; Hawley S; Newcomb LF; Lin DW; Nelson PS; Feng Z; Boyer HD; Tretiakova MS; True LD; Vakar-Lopez F; Carroll PR; Cooperberg MR; Chan E; Simko J; Fazli L; Gleave M; Hurtado-Coll A; Thompson IM; Troyer D; McKenney JK; Wei W; Choyke PL; Bratslavsky G; Turkbey B; Siemens DR; Squire J; Peng YP; Brooks JD; Jamaspishvili T
    Mod Pathol; 2023 Oct; 36(10):100241. PubMed ID: 37343766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence and Prognostic Significance of PTEN Loss in African-American and European-American Men Undergoing Radical Prostatectomy.
    Tosoian JJ; Almutairi F; Morais CL; Glavaris S; Hicks J; Sundi D; Humphreys E; Han M; De Marzo AM; Ross AE; Tomlins SA; Schaeffer EM; Trock BJ; Lotan TL
    Eur Urol; 2017 May; 71(5):697-700. PubMed ID: 27477529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.